Study To Compare Safety and Pharmacokinetic Properties of Surfolase Capsule and HT-002-01 in Healthy Male Volunteers

Inclusion criteria

• healthy male subjects between the age of 20 and 55 years with body mass index between 18.5 and 25
• Volunteers without apriority of chronic disease
• Volunteers must be in good health as determined by the investigator based on a detailed medical history, full physical examination, electrocardiogram, laboratory tests and urinalysis
• Volunteers who comply with the protocol, understand and sign an informed consent

Exclusion criteria

• Sensitive response to acebrophylline and xanthine
• Galactose intolerance, Lapp lactase deficiency and Glucose-Galactose Malabsorption
• Known history of renal, hepatic, respiratory, neurologic, endocrine, cardiac vascular and hematopoietic disease, especially gallstone
• Known history of gastrointestinal disease which affects the absorption of medicine.
• Excluded by screening tests
• Upper limit of AST, ALT>1.25 times Upper limit of total bilirubin>1.5 times
• Estimated GFR<80mL/min/1.73m2)
• systolic blood pressure < 90 or > 150, diastolic blood pressure <50 or >100
• Known history of drug abuse
• caffeine>5cups/day, alcohol>210g/week, 10 more cigarettes/day
• Use of any prescription drug within 14days or over-the-counter (OTC) medication within 7 days prior to dosing
• Participation in any clinical investigation within 60 days prior to study start
• Donation of blood within 60 days, donation of component blood within 30days
• Judged by the investigators to be undesirable as subjects